For some time now the FDA has been investigating problems with the popular diabetes drug Avandia, including heart attacks, fluid build up and heart failure. Despite these concerns the FDA decided not to remove Avandia from the market, However, on Friday the FDA announced that GlaxoSmithKline Plc, maker of Avandia, and Takeda Pharmaceutical Company Ltd., which makes the drug Actos, have agreed to add “black-box” warnings to their products. These warnings, the most severe that prescription drugs can bear, stress that the medicines may cause or worsen heart failure and that patients should be closely monitored. The warnings also apply to other drugs which include the active ingredient in Avandia or Actos.
Comments are closed.